CSL Behring Launches Innovative Test Kit Designed to Improve Diagnosis of Alpha-1

  CSL Behring Launches Innovative Test Kit Designed to Improve Diagnosis of
                                   Alpha-1

Alpha-1 is a Serious Medical Condition That Is Often Misdiagnosed as COPD or
Asthma

PR Newswire

KING OF PRUSSIA, Pa., Nov. 25, 2013

KING OF PRUSSIA, Pa., Nov. 25, 2013 /PRNewswire/ --CSL Behring today
announced the availability of DNA[1] Advanced Alpha-1 Screening^TM (DNA[1]), a
new test that aims to improve diagnosis of Alpha-1 Antitrypsin Deficiency
(Alpha-1). Launched during Alpha-1 Awareness Month, DNA[1] is the only
comprehensive Alpha-1 test available that identifies known and unknown
clinically relevant genetic variants to help physicians achieve an accurate
diagnosis.

Alpha-1 is a serious hereditary condition that can cause lung disease and/or
liver disease. It is often misdiagnosed as COPD, asthma or emphysema because
the symptoms are similar: shortness of breath, chronic cough, difficulty
breathing, and wheezing.^1 On average, people with Alpha-1 will see three
doctors over seven years before they are accurately diagnosed.^2 During that
time, lung damage progresses. The American Thoracic Society and European
Respiratory Society recommend screening adults with COPD, emphysema, or
irreversible asthma for Alpha-1–associated emphysema.

"Early diagnosis and treatment of Alpha-1 is important to help prevent
irreversible lung and/or liver damage," said Friedrich Kueppers, M.D.,
Professor of Medicine at Temple University School of Medicine. "CSL Behring's
DNA[1] test allows physicians to quickly and efficiently diagnose those with
Alpha-1. The test also identifies other genetic mutations that may lead to
Alpha-1 related emphysema that current testing technology might be missing."

DNA[1] Advanced Alpha-1 Screening was developed by Biocerna LLC and laboratory
testing of the kits is provided by the company. DNA[1] offers test results for
the following:

  oClinical chemistry – Blood spot assay to test patient alpha-1 antitrypsin
    (AAT) levels, as well as a C-reactive protein (CRP) test to provide full
    clinical analysis
  oTargeted genotyping – Identifies all known, clinically relevant variants,
    including S, Z, and F
  oNext generation sequencing – Sequencing of the SERPINA1 gene to identify
    unknown variants
  oIsoelectric focus – Results compared to genetic results as a confirmatory
    step 

"For the 100,000 Americans who are estimated to be living with Alpha-1, a
healthy and fulfilling lifestyle can be maintained with the proper treatment,"
said John Walsh, President and CEO of the Alpha-1 Foundation. "The first step
is taking a simple test, such as DNA[1], to ensure an accurate diagnosis for
all Alpha-1 deficient patients. Once diagnosed, an appropriate treatment plan
can be developed."

"CSL Behring is dedicated to the healthcare communities that we serve," said
Lynne Powell, Senior Vice President, North America Commercial Operations, CSL
Behring. "This dedication includes improving the ways in which rare and/or
serious diseases, such as Alpha-1, are tested and diagnosed. We are proud to
offer an advanced Alpha-1 screening test for the estimated 90 percent of
patients who are living with Alpha-1 but have not been properly diagnosed."

To order a DNA[1] Advanced Alpha-1 Screening ^ test kit, please call toll-free
1-888-508-6978. The test must be administered by a healthcare professional. 

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease, and neurological
disorders in certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic
diseases in the newborn. CSL Behring operates one of the world's largest
plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL
Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne,
Australia. For more information, visit www.cslbehring.com.

Media Contact:
Greg Healy
Senior Manager, Public Relations & Communications
CSL Behring
1-610-878-4841
greg.healy@cslbehring.com

^1 Alpha-1 Foundation -- What is Alpha1? Alpha1 Fast Facts. Available at:
http://www.alpha-1foundation.org/alphas/?c=01-What-is-Alpha-1-Alphas. Accessed
on November 11, 2013.

^2 COPD International Network-You Are Not Alone. Available at
http://www.copdinternational.com/Library/alpha-1.htm. Accessed on November 11,
2013.

SOURCE CSL Behring

Website: http://www.cslbehring.com
 
Press spacebar to pause and continue. Press esc to stop.